Steve Scala
Stock Analyst at TD Cowen
(2.84)
# 1,533
Out of 5,182 analysts
33
Total ratings
74.07%
Success rate
13.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Hold | $100 → $120 | $120.87 | -0.72% | 2 | Jan 20, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $48.57 | -7.35% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $208.84 | +7.74% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $59.60 | -1.01% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $203.49 | -53.31% | 1 | Aug 12, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $28.32 | +12.99% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $935.58 | -46.56% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $154.03 | -31.83% | 4 | Feb 1, 2021 |
Merck & Co.
Jan 20, 2026
Maintains: Hold
Price Target: $100 → $120
Current: $120.87
Upside: -0.72%
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $48.57
Upside: -7.35%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $208.84
Upside: +7.74%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $59.60
Upside: -1.01%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $203.49
Upside: -53.31%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $28.32
Upside: +12.99%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $935.58
Upside: -46.56%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $154.03
Upside: -31.83%